• Explore /
  • Poster
  • / PRINCE: Phase I trial of <sup>177</sup>Lu-PSMA-617 in combination with pembrolizumab in patients with metastatic castration-resistant prostate cancer (mCRPC).

PRINCE: Phase I trial of 177Lu-PSMA-617 in combination with pembrolizumab in patients with metastatic castration-resistant prostate cancer (mCRPC).

Abstract Video & Slides Poster

Authors

null

Shahneen Sandhu

Peter MacCallum Cancer Centre and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia

Shahneen Sandhu , Anthony M. Joshua , Louise Emmett , Lavinia Anne Spain , Lisa Horvath , Megan Crumbaker , Angelyn Anton , Roslyn Wallace , Anupama Pasam , Mathias Bressel , Erin Cassidy , Patricia Banks , Nattakorn Dhiantravan , Timothy J. Akhurst , Aravind Ravi Kumar , Ramin Alipour , Mark Scalzo , Scott Williams , Rodney Hicks , Michael S Hofman

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Genitourinary Cancer—Prostate, Testicular, and Penile

Track

Genitourinary Cancer—Prostate, Testicular, and Penile

Sub Track

Prostate Cancer– Advanced/Castrate-Resistant

Clinical Trial Registration Number

NCT03658447

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 5017)

DOI

10.1200/JCO.2022.40.16_suppl.5017

Abstract #

5017

Poster Bd #

201

Abstract Disclosures

Similar Posters

First Author: Zuzana Sirotova

First Author: Peter C.C. Fong

First Author: Evan Y. Yu

First Author: Louise Kathleen Kostos